Adjuvant and Neoadjuvant Immunotherapy in Non-small Cell Lung Cancer

Area of Science:

• Oncology
• Immunotherapy

Background:

• Immune checkpoint blockade has significantly advanced the treatment of advanced non-small cell lung cancer (NSCLC).
• The success in metastatic disease has spurred interest in applying these therapies to earlier stages of NSCLC.
• Clinical trials are actively investigating checkpoint blockade in both adjuvant and neoadjuvant settings for NSCLC.

Purpose of the Study:

• To evaluate the safety and feasibility of neoadjuvant checkpoint inhibitors in resectable NSCLC.
• To assess the pathologic response rates following neoadjuvant immunotherapy in NSCLC.
• To compare neoadjuvant chemotherapy combined with checkpoint blockade against chemotherapy alone in phase 3 trials for resectable NSCLC.

Main Methods:

• Administration of checkpoint inhibitors in the neoadjuvant setting.
• Analysis of resection specimens to determine pathologic response.
• Ongoing phase 3 clinical trials comparing combination therapy (chemotherapy + checkpoint blockade) with chemotherapy alone.

Main Results:

• Early trials indicate that neoadjuvant checkpoint inhibitors are safe and feasible.
• Pathologic response rates in resection specimens are encouraging.
• Several phase 3 studies are underway to confirm efficacy.

Conclusions:

• Neoadjuvant immune checkpoint blockade shows promise for resectable non-small cell lung cancer.
• Further investigation in phase 3 trials is crucial to establish its role in earlier-stage NSCLC treatment.
• Combination therapy with chemotherapy and checkpoint blockade is a key area of ongoing research.